SARS-CoV-2 spike therapeutic antibodies in the age of variants
- PMID: 33871567
- PMCID: PMC8056769
- DOI: 10.1084/jem.20210198
SARS-CoV-2 spike therapeutic antibodies in the age of variants
Abstract
Christos Kyratsous, Vice President of Research, Infectious Diseases, and Viral Vector Technologies at Regeneron Pharmaceuticals, and Alina Baum, Associate Director, Infectious Diseases Associate at Regeneron Pharmaceuticals, discuss the development of antibody therapeutics targeting the spike protein of SARS-CoV-2.
© 2021 Baum and Kyratsous.
References
-
- Baum, A., et al. . 2020a. Science. 10.1126/science.abe2402 - DOI
-
- Baum, A., et al. . 2020b. Science. 10.1126/science.abd0831 - DOI
-
- Center for Disease Control and Prevention . 2021. SARS-CoV-2 Variant Classifications and Definitions. https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveill....
-
- Chen, P., et al. . 2021. N. Engl. J. Med. 10.1056/NEJMoa2029849 - DOI
-
- Copin, R., et al. . 2021. bioRxiv. 10.1101/2021.03.10.434834 (Preprint posted March 27, 2021) - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous